U.S. markets open in 26 minutes
  • S&P Futures

    4,575.25
    +17.25 (+0.38%)
     
  • Dow Futures

    35,728.00
    +108.00 (+0.30%)
     
  • Nasdaq Futures

    15,583.00
    +87.25 (+0.56%)
     
  • Russell 2000 Futures

    2,317.70
    +7.40 (+0.32%)
     
  • Crude Oil

    84.13
    +0.37 (+0.44%)
     
  • Gold

    1,800.80
    -6.00 (-0.33%)
     
  • Silver

    24.42
    -0.17 (-0.70%)
     
  • EUR/USD

    1.1624
    +0.0009 (+0.08%)
     
  • 10-Yr Bond

    1.6340
    -0.0010 (-0.06%)
     
  • Vix

    14.99
    -0.44 (-2.85%)
     
  • GBP/USD

    1.3803
    +0.0035 (+0.25%)
     
  • USD/JPY

    114.0930
    +0.3940 (+0.35%)
     
  • BTC-USD

    62,599.38
    -175.12 (-0.28%)
     
  • CMC Crypto 200

    1,502.30
    +1,259.62 (+519.05%)
     
  • FTSE 100

    7,273.84
    +51.02 (+0.71%)
     
  • Nikkei 225

    29,106.01
    +505.60 (+1.77%)
     

New Study Data Confirms NLS Pharmaceutics' Mazindol Orexin Pathway Activation For Sleeping Disorder

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • NLS Pharmaceutics Ltd (NASDAQ: NLSP) has announced new study data which support the mechanism of action for mazindol, the active compound in the Company's lead product candidate to treat narcolepsy, Quilience.

  • Narcolepsy is a chronic sleep disorder caused by a deficiency in orexin, a neuropeptide that regulates the sleep-wake cycle.

  • The new data confirm mazindol's Orexin-2 receptor (OX2R) agonist activity.

  • In the pre-clinical study conducted by the Department of Biomedical Sciences at the University of Lausanne and sponsored by NLS, mice genetically modified not to express OX2R (Knock-Out mice) and Wild-Type mice (normal mice) were investigated for psychostimulant effects when mazindol was administered.

  • The study demonstrated that Knock Out mice were 70% less sensitive to mazindol than normal mice, confirming mazindol's potent activity as an OX2R agonist.

  • Price Action: NLSP shares are up 0.58% at $3.39 on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.